---
layout: default
title: Damoctocog Alfa Pegol
parent: 僅模型預測 (L5)
nav_order: 126
evidence_level: L5
indication_count: 0
---

# Damoctocog Alfa Pegol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Damoctocog Alfa Pegol: Evaluation Pending — No TxGNN Repurposing Predictions Available

## Summary

Damoctocog alfa pegol (DrugBank ID: DB14700) is a PEGylated recombinant coagulation factor VIII biological product currently not marketed in Denmark.
The TxGNN pipeline returned **no repurposing candidates** for this drug, and critical data items — including mechanism of action and safety profile — are absent from the current evidence pack.
A full drug repurposing evaluation cannot be completed until these gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in evidence pack |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no predictions generated; evaluation not possible) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why Were No Predictions Generated?

The query log confirms that the DrugBank lookup succeeded (DB14700, 1 result), meaning the drug identity was resolved. However, the prediction pipeline returned an empty candidate list. This typically occurs for one of three reasons:

1. **Knowledge graph coverage gap**: The TxGNN knowledge graph may not contain sufficient edges connecting damoctocog alfa pegol to disease nodes, because it is a large-molecule biological (PEGylated recombinant FVIII) rather than a small-molecule drug. TxGNN's training data is weighted toward small molecules.

2. **Missing indication seed**: The `original_indications` field is empty, which means the pipeline had no approved indication anchor from which to calculate mechanistic similarity scores across disease space.

3. **MOA data absent**: Without a documented mechanism of action in the evidence pack, the model cannot leverage mechanism-based feature vectors to rank candidate indications.

Until the original indication and MOA are populated, no meaningful repurposing signal can be extracted from TxGNN for this compound.

---

## Denmark Market Information

Damoctocog alfa pegol holds **no marketing authorisations** in Denmark, and is recorded as not marketed. No product entries are available from Lægemiddelstyrelsen or the centralised EMA register in this evidence pack.

> **Note for the reviewer**: Damoctocog alfa pegol (brand name Jivi®, BAY 94-9027) has a centralised EMA Marketing Authorisation for prophylaxis and treatment of bleeding in adults with haemophilia A (congenital factor VIII deficiency). If this drug is intended for evaluation, the evidence pack data retrieval step should be repeated with an EMA-sourced licence lookup, as the current pack shows zero records — this is likely a retrieval gap rather than a true absence of authorisation.

---

## Safety Considerations

No safety data were retrieved for this compound in the current evidence pack. Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack contains no TxGNN predictions, no original indication records, no mechanism of action, and no safety data — the minimum inputs required to generate or evaluate a repurposing hypothesis are all absent.

**To proceed, the following is needed:**

- **Resolve Blocking data gap (DG001):** Retrieve the full SmPC from the EMA product page (EMEA/H/C/004178) to extract approved indication text, key warnings, and contraindications.
- **Resolve High-severity data gap (DG002):** Query DrugBank for the documented MOA of DB14700 (recombinant factor VIII mechanism — replacement of deficient coagulation factor VIII).
- **Populate `original_indications`:** Insert the approved EMA indication (haemophilia A) so the TxGNN pipeline has an anchor disease node.
- **Re-run the TxGNN prediction pipeline** once the above three items are in place.
- **Verify EMA licence retrieval:** Confirm that the Lægemiddelstyrelsen / EMA data connector is correctly querying centralised authorisations, as the 0-licence result appears inconsistent with the drug's known approval status in Europe.

---

> ⚠️ **Disclaimer**: This report is for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

